Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipilimumab in Advanced Pancreatic Adenocarcinoma
NCT00112580Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2005
- Primary completion
- Jun 2009
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ipilimumab in pancreatic adenocarcinoma (PDAC), sponsored by Bristol Myers Squibb. Started Jul 2005; status: completed.
02
Drugs
ipilimumab
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT00112580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00112580.